CBLL

MKT CAP:$797M

CeriBell, Inc.

Market Cap

$797M

Healthcare·Medical - Devices·🇺🇸 United States·NASDAQ

Healthcare·Medical - Devices·🇺🇸·NASDAQ

Stock Price

$21.63+$0.32 (+1.53%)

Apr 22, 2026

Company Details

CeriBell, Inc. develops AI based point-of-care electroencephalography (EEG) technology for the detection and treatment of neurological conditions. The company develops Ceribell System, a novel, point-of-care EEG platform to address the unme...

CEO

Xingjuan Chao

IPO Date

Oct 11, 2024

Website

ceribell.com

Key Metrics TTM

Revenue

$89M

+47.3% YoY

Net Income

-$53M

EPS (Diluted)

-$1.47

Free Cash Flow

-$42M

Revenue / Share

$2.39

Gross Margin

87.9%

Operating Margin

-65.6%

Net Margin

-60.0%

FCF Margin

-47.0%

P/S

8.9x

P/E

—

Earnings Reports

Q1 2026

May 7, 2026

PENDING

FY 2025

Feb 24, 2026

$89M+36.1%EPS -$1.46

Q4 2025

Feb 24, 2026

$25M+33.7%EPS -$0.36

Q3 2025

Nov 4, 2025

$23M+31.4%EPS -$0.37

Q2 2025

Aug 5, 2025

$21MEPS -$0.38

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 23	$10M	$9M	-$7M
Q2 23	$10M	$9M	-$7M
Q3 23	$12M	$10M	-$7M
Q4 23	$13M	$11M	-$8M
Q3 24	$17M	$15M	-$10M
Q4 24	$19M	$16M	-$13M
Q1 25	$20M	$18M	-$14M
Q2 25	$21M	$19M	-$15M
Q3 25	$23M	$20M	-$15M
Q4 25	$25M	$22M	-$15M

Valuation

Quarter	P/S	P/E
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	19.2x	—
Q3 24	16.6x	—
Q4 24	14.5x	—
Q1 25	8.6x	—
Q2 25	8.7x	—
Q3 25	5.0x	—
Q4 25	8.8x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$8M	-$8M
Q2 23	-$8M	-$8M
Q3 23	-$7M	-$8M
Q4 23	-$7M	-$7M
Q3 24	-$9M	-$9M
Q4 24	-$10M	-$10M
Q1 25	-$11M	-$12M
Q2 25	-$8M	-$8M
Q3 25	-$11M	-$12M
Q4 25	-$11M	-$11M

Capital Expenditures

Quarter	CapEx
Q1 23	$694.5K
Q2 23	$694.5K
Q3 23	$156.0K
Q4 23	$683.0K
Q3 24	$567.0K
Q4 24	$357.0K
Q1 25	$279.0K
Q2 25	$71.0K
Q3 25	$369.0K
Q4 25	$179.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q3 24	+67.9%	+55.1%
Q4 24	+81.0%	+79.6%
Q1 25	+76.5%	+84.8%
Q2 25	+61.4%	+68.1%
Q3 25	+31.4%	+37.2%
Q4 25	+33.7%	+25.3%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$648.0K	6.3%
Q2 23	$648.0K	6.3%
Q3 23	$637.0K	5.5%
Q4 23	$3M	20.3%
Q3 24	$1M	8.0%
Q4 24	$2M	11.9%
Q1 25	$2M	11.5%
Q2 25	$3M	14.9%
Q3 25	$0	0.0%
Q4 25	$3M	13.6%

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q1 23	$2M	$5M	$9M
Q2 23	$2M	$5M	$9M
Q3 23	$2M	$5M	$10M
Q4 23	$3M	$6M	$11M
Q3 24	$3M	$9M	$13M
Q4 24	$4M	$10M	$15M
Q1 25	$4M	$10M	$18M
Q2 25	$5M	$11M	$17M
Q3 25	$5M	$11M	$19M
Q4 25	$5M	$12M	$19M

Revenue Segments

Quarter	Product	Subscription
Q1 25	$16M	$5M
Q2 25	$16M	$5M
Q3 25	$17M	$6M
Q4 25	$19M	$6M

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 23	$34M	$0	$34M
Q1 24	$0	$0	$0
Q2 24	$24M	$0	$24M
Q3 24	$14M	$0	$14M
Q4 24	$194M	$0	$194M
Q1 25	$153M	$29M	$183M
Q2 25	$40M	$137M	$177M
Q3 25	$24M	$145M	$169M
Q4 25	$40M	$119M	$159M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 23	5M	—	—
Q2 23	5M	0.0%	—
Q3 23	23M	+345.2%	—
Q4 23	23M	0.0%	—
Q3 24	34M	+45.9%	+549.3%
Q4 24	31M	-8.3%	+495.6%
Q1 25	36M	+15.0%	+53.8%
Q2 25	36M	+1.1%	+55.6%
Q3 25	37M	+1.4%	+8.2%
Q4 25	37M	+1.1%	+19.3%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	—	—
Q3 24	—	—
Q4 24	$66.0K	281
Q1 25	$72.9K	281
Q2 25	$75.4K	281
Q3 25	$80.4K	281
Q4 25	$75.8K	327

Revenue / Employee